Fisher Asset Management LLC Increases Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Fisher Asset Management LLC lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 15.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 106,871 shares of the medical research company's stock after buying an additional 14,135 shares during the quarter. Fisher Asset Management LLC owned approximately 0.38% of Bio-Rad Laboratories worth $35,108,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC boosted its position in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after purchasing an additional 87 shares in the last quarter. Gladius Capital Management LP bought a new stake in Bio-Rad Laboratories during the third quarter valued at about $32,000. Asset Planning Inc bought a new stake in Bio-Rad Laboratories during the fourth quarter valued at about $33,000. UMB Bank n.a. boosted its position in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in Bio-Rad Laboratories during the third quarter valued at about $55,000. Institutional investors own 65.24% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BIO. Wells Fargo & Company dropped their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $395.20.

Bio-Rad Laboratories Stock Down 1.9 %

NYSE BIO traded down $4.86 during trading on Tuesday, hitting $251.59. The company's stock had a trading volume of 120,496 shares, compared to its average volume of 229,736. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The company has a market cap of $7.05 billion, a PE ratio of -3.87 and a beta of 0.90. The business's 50 day simple moving average is $325.57 and its 200-day simple moving average is $332.16. Bio-Rad Laboratories, Inc. has a fifty-two week low of $248.22 and a fifty-two week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.